Synthetic dopamine (DA) precursors (e.g., levodopa), DA agonists (e.g., pergolide), and monoamine oxidase-B (MAO-B) inhibitors (e.g., selegiline) are frequently used to manage PD, but they can lead to serious side effects such as cardiopathy and dyskinesia. Here, MAOB is linked to drug-induced dyskinesia.